神経内分泌腫瘍治療の世界市場2019-2023

◆英語タイトル:Global Neuroendocrine Tumors Therapeutics Market 2019-2023
◆商品コード:IRTNTR31154
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年4月10日
◆ページ数:129
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥272,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥327,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、神経内分泌腫瘍治療の世界市場について調査・分析し、市場概要、市場環境、神経内分泌腫瘍治療市場規模、種類別(ソマトスタチンアナログ、ターゲット治療、その他治療)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・神経内分泌腫瘍治療の世界市場概要
・神経内分泌腫瘍治療の世界市場環境
・神経内分泌腫瘍治療の世界市場動向
・神経内分泌腫瘍治療の世界市場規模
・神経内分泌腫瘍治療の世界市場:業界構造分析
・神経内分泌腫瘍治療の世界市場:種類別(ソマトスタチンアナログ、ターゲット治療、その他治療)
・神経内分泌腫瘍治療の世界市場:地域別市場規模・分析
・神経内分泌腫瘍治療の北米市場規模・予測
・神経内分泌腫瘍治療のヨーロッパ・中東・アフリカ市場規模・予測
・神経内分泌腫瘍治療のアジア太平洋市場規模・予測
・神経内分泌腫瘍治療の主要国分析
・神経内分泌腫瘍治療の世界市場:意思決定フレームワーク
・神経内分泌腫瘍治療の世界市場:成長要因、課題
・神経内分泌腫瘍治療の世界市場:競争環境
・神経内分泌腫瘍治療の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market

The increasing research grants and funding are contributing to the neuroendocrine tumors therapeutics market growth in the forthcoming years. Various government and non-government organizations are focusing on providing grants and funding to create an awareness about neuroendocrine tumors. These programs also help in better and quicker development of therapies for the treatment of neuroendocrine tumors. Furthermore, the grants are expected to accelerate the research and strengthen the drug development pipeline of neuroendocrine tumors, thus, impacting the market growth positively over the next few years. Technavio’s analysts have predicted that the neuroendocrine tumors therapeutics market will register a CAGR of close to 9% by 2023.

Market Overview

The advent of radiolabeled drugs

One of the growth drivers of the global neuroendocrine tumor’s therapeutics market is the advent of radiolabeled drugs. Due to their high efficacy with less adverse effects, such novel drugs receive high adoption from medical practitioners, which broadens the overall patient base and drives the market growth.

Increasing preference for alternative treatments

One of the challenges in the growth of the global neuroendocrine tumor’s therapeutics market is the increasing preference for alternative treatments. Therapeutic approaches remain costly, more time consuming, and non-remissive in nature, which makes them less preferred treatment options among patients as well as medical practitioners, which poses a challenge to market growth.

For the detailed list of factors that will drive and challenge the growth of the neuroendocrine tumors therapeutics market during 2019-2023, view our report.

Competitive Landscape

The market appears to be highly concentrated with the presence of a few market players. Vendors are focusing on extensive research for identifying the attributes of neuroendocrine tumors through a genomic approach, as the identification of mutated genes is one of the biggest challenges for developing target therapies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Somatostatin analogs – Market size and forecast 2018-2023

Targeted therapies – Market size and forecast 2018-2023

Other therapies – Market size and forecast 2018-2023

Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

F. Hoffmann-La Roche Ltd

Ipsen Pharma

Merck & Co., Inc

Novartis AG

Pfizer Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global pharmaceuticals market

Exhibit 02: Segments of global pharmaceuticals market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Type – Market share 2018-2023 (%)

Exhibit 18: Comparison by type

Exhibit 19: Somatostatin analogs – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: Somatostatin analogs – Year-over-year growth 2019-2023 (%)

Exhibit 21: Targeted therapies – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Targeted therapies – Year-over-year growth 2019-2023 (%)

Exhibit 23: Other therapies – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: Other therapies – Year-over-year growth 2019-2023 (%)

Exhibit 25: Market opportunity by type

Exhibit 26: Customer landscape

Exhibit 27: Market share by geography 2018-2023 (%)

Exhibit 28: Geographic comparison

Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 30: North America – Year-over-year growth 2019-2023 (%)

Exhibit 31: Top 3 countries in North America

Exhibit 32: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 33: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 34: Top 3 countries in Europe

Exhibit 35: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 36: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 37: Top 3 countries in Asia

Exhibit 38: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 39: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 40: Top 3 countries in ROW

Exhibit 41: Key leading countries

Exhibit 42: Market opportunity

Exhibit 43: Impact of drivers and challenges

Exhibit 44: Strategic alliances in global neuroendocrine tumors therapeutics market: Overview

Exhibit 45: Vendor landscape

Exhibit 46: Landscape disruption

Exhibit 47: Vendors covered

Exhibit 48: Vendor classification

Exhibit 49: Market positioning of vendors

Exhibit 50: F. Hoffmann-La Roche Ltd – Vendor overview

Exhibit 51: F. Hoffmann-La Roche Ltd – Business segments

Exhibit 52: F. Hoffmann-La Roche Ltd – Organizational developments

Exhibit 53: F. Hoffmann-La Roche Ltd – Geographic focus

Exhibit 54: F. Hoffmann-La Roche Ltd – Segment focus

Exhibit 55: F. Hoffmann-La Roche Ltd – Key offerings

Exhibit 56: F. Hoffmann-La Roche Ltd – Key customers

Exhibit 57: Ipsen Pharma – Vendor overview

Exhibit 58: Ipsen Pharma – Business segments

Exhibit 59: Ipsen Pharma – Organizational developments

Exhibit 60: Ipsen Pharma – Geographic focus

Exhibit 61: Ipsen Pharma – Segment focus

Exhibit 62: Ipsen Pharma – Key offerings

Exhibit 63: Ipsen Pharma – Key customers

Exhibit 64: Merck & Co., Inc – Vendor overview

Exhibit 65: Merck & Co., Inc – Business segments

Exhibit 66: Merck & Co., Inc – Organizational developments

Exhibit 67: Merck & Co., Inc – Geographic focus

Exhibit 68: Merck & Co., Inc – Segment focus

Exhibit 69: Merck & Co., Inc – Key offerings

Exhibit 70: Merck & Co., Inc – Key customers

Exhibit 71: Novartis AG – Vendor overview

Exhibit 72: Novartis AG – Business segments

Exhibit 73: Novartis AG – Organizational developments

Exhibit 74: Novartis AG – Geographic focus

Exhibit 75: Novartis AG – Segment focus

Exhibit 76: Novartis AG – Key offerings

Exhibit 77: Novartis AG – Key customers

Exhibit 78: Pfizer Inc. – Vendor overview

Exhibit 79: Pfizer Inc. – Business segments

Exhibit 80: Pfizer Inc. – Organizational developments

Exhibit 81: Pfizer Inc. – Geographic focus

Exhibit 82: Pfizer Inc. – Segment focus

Exhibit 83: Pfizer Inc. – Key offerings

Exhibit 84: Pfizer Inc. – Key customers

Exhibit 85: Validation techniques employed for market sizing



【掲載企業】

F. Hoffmann-La Roche Ltd, Ipsen Pharma, Merck & Co., Inc, Novartis AG, Pfizer Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[神経内分泌腫瘍治療の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆